nach oben

The International Journal of Cardiovascular Imaging

Erschienen in:

12.01.2024 | Original Paper

Correlation of ventricle epicardial fat volume and triglyceride-glucose index in patients with chronic heart failure

verfasst von: Iokfai Cheang, Xu Zhu, Xinyi Lu, Shi Shi, Xin Yue, Yuan Tang, Yujie Gao, Shengen Liao, Wenming Yao, Yanli Zhou, Haifeng Zhang, Yinsu Zhu, Yi Xu, Xinli Li

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

To explore the association of ventricle epicardial fat volume (EFV) calculated by cardiac magnetic resonance (CMR) and the insulin resistance indicator of triglyceride–glucose (TyG) index in patients with chronic HF (CHF), this retrospective cohort study included adult CHF patients with confirmed diagnosis of heart failure from January 2018 to December 2020. All patients underwent 3.0T CMR, and EFV were measured under short-axis cine. Spearman correlation, multivariate linear regression, and restricted cubic spline (RCS) regression were used to analyze their association. There were 516 patients with CHF, of whom 69.8% were male. Median EFV was 57.14mL and mean TyG index was 8.48. Spearman correlation analysis showed that TyG index was significantly correlated with the EFV in CHF patients (r = 0.247, P < 0.001). Further analysis showed that TyG index levels were significantly associated with EFV as both continuous variables (Unstandardized β = 6.556, P < 0.001) and across the increasing quartiles (β = 7.50, 95% CI [1.41, 13.59], P < 0.05). RCS demonstrated there were a positive trend and linear association between EFV and TyG index in CHF patients (P for nonliearity = 0.941). In patients with CHF, the TyG index was positively and linearly associated with the EFV, which supports the metabolic roles of epicardial adipose tissue regarding insulin resistance.

Nur mit Berechtigung zugänglich

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(18):e895–e1032. https://doi.org/10.1161/CIR.0000000000001063CrossRefPubMed

Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(10):1169–1186. https://doi.org/10.1002/ejhf.1531CrossRefPubMed

Roger VL (2021) Epidemiology of heart failure: a contemporary perspective. Circ Res 128(10):1421–1434. https://doi.org/10.1161/CIRCRESAHA.121.318172CrossRefPubMed

Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B et al (2019) China hypertension survey investigators. prevalence of heart failure and left ventricular dysfunction in China: the China hypertension survey, 2012–2015. Eur J Heart Fail 21(11):1329–1337. https://doi.org/10.1002/ejhf.1629CrossRefPubMed

Greene SJ, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J et al (2017) Hospitalization for recently diagnosed versus worsening chronic heart failure: from the ASCEND-HF Trial. J Am Coll Cardiol 69(25):3029–3039. https://doi.org/10.1016/j.jacc.2017.04.043CrossRefPubMed

Psotka MA, Fonarow GC, Allen LA, Joynt Maddox KE, Fiuzat M, Heidenreich P et al (2020) The hospital readmissions reduction program: nationwide perspectives and recommendations: a JACC: heart failure position paper. JACC Heart Fail 8(1):1–11. https://doi.org/10.1016/j.jchf.2019.07.012CrossRefPubMed

Wu C, Zhang Z, Zhang W, Liu X (2022) Mitochondrial dysfunction and mitochondrial therapies in heart failure. Pharmacol Res 175:106038. https://doi.org/10.1016/j.phrs.2021.106038CrossRefPubMed

Smith U, Kahn BB (2016) Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med 280(5):465–475. https://doi.org/10.1111/joim.12540CrossRefPubMedPubMedCentral

Hammarstedt A, Gogg S, Hedjazifar S, Nerstedt A, Smith U (2018) Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity. Physiol Rev 98(4):1911–1941. https://doi.org/10.1152/physrev.00034.2017CrossRefPubMed

10.

Ding X, Wang X, Wu J, Zhang M, Cui M (2021) Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol 20(1):76. https://doi.org/10.1186/s12933-021-01268-9CrossRefPubMedPubMedCentral

11.

Kahleova H, Matoulek M, Malinska H, Oliyarnik O, Kazdova L, Neskudla T et al (2011) Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with type 2 diabetes. Diabet Med 28(5):549–559. https://doi.org/10.1111/j.1464-5491.2010.03209.xCrossRefPubMedPubMedCentral

12.

Sanz CM, Ruidavets JB, Bongard V, Marquié JC, Hanaire H, Ferrières J et al (2013) Relationship between markers of insulin resistance, markers of adiposity, HbA1c, and cognitive functions in a middle-aged population-based sample: the MONA LISA study. Diabetes Care 36(6):1512–1521. https://doi.org/10.2337/dc12-1017CrossRefPubMedPubMedCentral

13.

Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY et al (2020) Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol 19(1):80. https://doi.org/10.1186/s12933-020-01054-zCrossRefPubMedPubMedCentral

14.

Guo W, Zhao L, Mo F, Peng C, Li L, Xu Y et al (2021) The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract 177:108786. https://doi.org/10.1016/j.diabres.2021.108786CrossRefPubMed

15.

Tao LC, Xu JN, Wang TT, Hua F, Li JJ (2022) Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol 21(1):68. https://doi.org/10.1186/s12933-022-01511-xCrossRefPubMedPubMedCentral

16.

Nagy E, Jermendy AL, Merkely B, Maurovich-Horvat P (2017) Clinical importance of epicardial adipose tissue. Arch Med Sci 13(4):864–874. https://doi.org/10.5114/aoms.2016.63259CrossRefPubMed

17.

Blumensatt M, Fahlbusch P, Hilgers R, Bekaert M, Herzfeld de Wiza D, Akhyari P et al (2017) Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial β-oxidation in cardiomyocytes via activation of the cardiac renin-angiotensin system and induction of miR-208a. Basic Res Cardiol 112(1):2. https://doi.org/10.1007/s00395-016-0591-0CrossRefPubMed

18.

Nalliah CJ, Bell JR, Raaijmakers AJA, Waddell HM, Wells SP, Bernasochi GB et al (2020) Epicardial adipose tissue accumulation confers atrial conduction abnormality. J Am Coll Cardiol 76(10):1197–1211. https://doi.org/10.1016/j.jacc.2020.07.017CrossRefPubMed

19.

Christensen RH, Hansen CS, von Scholten BJ, Jensen MT, Pedersen BK, Schnohr P et al (2019) Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes. Diabetes Obes Metab 21(8):2006–2011. https://doi.org/10.1111/dom.13758CrossRefPubMed

20.

Iacobellis G (2022) Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 19(9):593–606. https://doi.org/10.1038/s41569-022-00679-9CrossRefPubMedPubMedCentral

21.

Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 19(1):75. https://doi.org/10.1186/s12968-017-0389-8CrossRefPubMedPubMedCentral

22.

van Woerden G, van Veldhuisen DJ, Gorter TM, van Empel VPM, Hemels MEW, Hazebroek EJ et al (2021) Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid-range and preserved ejection fraction. Clin Cardiol 44(7):987–993. https://doi.org/10.1002/clc.23644CrossRefPubMedPubMedCentral

23.

Zhou Y, Yu M, Cui J, Hu F, Yang Z, Yuan J et al (2021) The predictive value of epicardial adipose tissue volume assessed by cardiac magnetic resonance for atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Int J Cardiovasc Imaging 37(4):1383–1393. https://doi.org/10.1007/s10554-020-02092-0CrossRefPubMed

24.

Xu L, Wu M, Chen S, Yang Y, Wang Y, Wu S et al (2022) Triglyceride-glucose index associates with incident heart failure: a cohort study. Diabetes Metab 101365. https://doi.org/10.1016/j.diabet.2022.101365

25.

Villasante Fricke AC, Iacobellis G (2019) Epicardial adipose tissue: clinical biomarker of Cardio-metabolic risk. Int J Mol Sci 20(23):5989. https://doi.org/10.3390/ijms20235989CrossRefPubMedPubMedCentral

26.

Nerlekar N, Muthalaly RG, Wong N, Thakur U, Wong DTL, Brown AJ, Marwick TH (2018) Association of volumetric epicardial adipose tissue quantification and cardiac structure and function. J Am Heart Assoc 7(23):e009975. https://doi.org/10.1161/JAHA.118.009975CrossRefPubMedPubMedCentral

27.

Cheang I, Zhu X, Yue X, Tang Y, Gao Y, Lu X et al (2023) Prognostic value of ventricle epicardial fat volume by cardiovascular magnetic resonance in chronic heart failure. iScience 26(5):106755. https://doi.org/10.1016/j.isci.2023.106755CrossRefPubMedPubMedCentral

28.

Mone P, De Gennaro S, Frullone S, Marro A, Santulli G (2023) Hyperglycemia drives the transition from pre-frailty to frailty: the monteforte study. Eur J Intern Med 111:135–137. https://doi.org/10.1016/j.ejim.2023.01.006Epub 2023 Jan 10. PMID: 36635128; PMCID: PMC10122706CrossRefPubMedPubMedCentral

29.

Pansini A, Lombardi A, Morgante M, Frullone S, Marro A, Rizzo M et al (2022) Hyperglycemia and physical impairment in frail hypertensive older adults. Front Endocrinol (Lausanne) 13:831556. https://doi.org/10.3389/fendo.2022.831556PMID: 35498439; PMCID: PMC9048203CrossRefPubMed

30.

Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F et al (2023) Stress hyperglycemia drives the risk of hospitalization for chest pain in patients with ischemia and nonobstructive coronary arteries (INOCA). Diabetes Care 46(2):450–454. https://doi.org/10.2337/dc22-0783PMID: 36478189; PMCID: PMC9887616CrossRefPubMed

31.

Chouchani ET, Kajimura S (2019) Metabolic adaptation and maladaptation in adipose tissue. Nat Metab 1(2):189–200. https://doi.org/10.1038/s42255-018-0021-8Epub 2019 Jan 21. PMID: 31903450; PMCID: PMC6941795CrossRefPubMedPubMedCentral

32.

Hasebe H, Yoshida K, Nogami A, Ieda M (2020) Difference in epicardial adipose tissue distribution between paroxysmal atrial fibrillation and coronary artery disease. Heart Vessels 35(8):1070–1078. https://doi.org/10.1007/s00380-020-01575-3CrossRefPubMed

33.

González N, Moreno-Villegas Z, González-Bris A, Egido J, Lorenzo Ó (2017) Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. Cardiovasc Diabetol 16(1):44. https://doi.org/10.1186/s12933-017-0528-4CrossRefPubMedPubMedCentral

34.

Parisi V, Cabaro S, D’Esposito V, Petraglia L, Conte M, Campana P et al (2020) Epicardial adipose tissue and IL-13 response to myocardial injury drives left ventricular remodeling after ST elevation myocardial infarction. Front Physiol 11:575181. https://doi.org/10.3389/fphys.2020.575181CrossRefPubMedPubMedCentral

35.

36.

Iacobellis G, Sharma AM (2007) Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Curr Pharm Des 13(21):2180–2184. https://doi.org/10.2174/138161207781039670CrossRefPubMed

37.

Li B, Po SS, Zhang B, Bai F, Li J, Qin F et al (2020) Metformin regulates adiponectin signalling in epicardial adipose tissue and reduces atrial fibrillation vulnerability. J Cell Mol Med 24(14):7751–7766. https://doi.org/10.1111/jcmm.15407CrossRefPubMedPubMedCentral

38.

Dozio E, Vianello E, Malavazos AE, Tacchini L, Schmitz G, Iacobellis G et al (2019) Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk? Int J Cardiol 292:218–224. https://doi.org/10.1016/j.ijcard.2019.04.039CrossRefPubMed

39.

Masson W, Lavalle-Cobo A, Nogueira JP (2021) Effect of SGLT2-inhibitors on epicardial adipose tissue: a meta-analysis. Cells 10(8):2150. https://doi.org/10.3390/cells10082150. PMID

40.

Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, Vargas-Delgado AP, Mancini D, Sartori S et al (2021) Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study. JACC Heart Fail 9(8):578–589. https://doi.org/10.1016/j.jchf.2021.04.014CrossRefPubMed

41.

Payne GA, Kohr MC, Tune JD (2012) Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol 165(3):659–669. https://doi.org/10.1111/j.1476-5381.2011.01370.xCrossRefPubMedPubMedCentral

42.

Packer M (2021) Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes. JACC Heart Fail 9(8):535–549. https://doi.org/10.1016/j.jchf.2021.05.019CrossRefPubMed

43.

Xourgia E, Papazafiropoulou A, Melidonis A (2018) Effects of antidiabetic drugs on epicardial fat. World J Diabetes 9(9):141–148. https://doi.org/10.4239/wjd.v9.i9.141CrossRefPubMedPubMedCentral

44.

Rossi VA, Gruebler M, Monzo L, Galluzzo A, Beltrami M (2023) The different pathways of epicardial adipose tissue across the heart failure phenotypes: from pathophysiology to therapeutic target. Int J Mol Sci 24(7):6838. https://doi.org/10.3390/ijms24076838CrossRefPubMedPubMedCentral

Titel: Correlation of ventricle epicardial fat volume and triglyceride-glucose index in patients with chronic heart failure
verfasst von: Iokfai Cheang
Xu Zhu
Xinyi Lu
Shi Shi
Xin Yue
Yuan Tang
Yujie Gao
Shengen Liao
Wenming Yao
Yanli Zhou
Haifeng Zhang
Yinsu Zhu
Yi Xu
Xinli Li
Publikationsdatum: 12.01.2024
Verlag: Springer Netherlands
Erschienen in: The International Journal of Cardiovascular Imaging / Ausgabe 4/2024
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI: https://doi.org/10.1007/s10554-024-03048-4

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Correlation of ventricle epicardial fat volume and triglyceride-glucose index in patients with chronic heart failure

Abstract

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Cardiac magnetic resonance-derived mitral annular plane systolic excursion: a robust indicator for risk stratification after myocardial infarction

Halved contrast medium dose coronary dual-layer CT-angiography – phantom study of tube current and patient characteristics

Morphological characteristics of in-stent restenosis with different degrees of area stenosis: an optical coherence tomography study

Longitudinal strain and myocardial work in symptomatic patients having recovered from COVID-19 and possible associations with the severity of the disease

Determination of viable myocardium through delayed enhancement cardiac magnetic resonance imaging combined with 18F-FDG PET myocardial perfusion/metabolic imaging before CABG

Photon-counting CT-angiography in pre-TAVR aortic annulus assessment: effects of retrospective vs. prospective ECG-synchronization on prosthesis valve selection

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Kardiologie